Gene synthesis companies establish measures to counter bioterrorism
By European Biotechnology Science and Industry News,
European Biotechnology Science and Industry News
| 11. 20. 2009
The five largest suppliers of synthetic DNA will establish common measures to prevent misuse of synthetically produced DNA by bioterorrists or criminals. Yesterday, Blue Heron Biotechnology, DNA2.0, GENEART, GenScript and Integrated DNA Technologies, which together represent an 80% share of the synthetic DNA market, announced the establishment of a common screening protocol that will be applied to every single synthetic gene order. "We are proud to announce the formation of the International Gene Synthesis Consortium", said John Mulligan, CSO of Blue Heron Biotechnology.
The IGSC's "Harmonized Screening Protocol" is comprised of the screening of gene sequences against a regulated pathogen database developed by the consortium and one or more of the internationally coordinated sequence reference databanks, such as NCBI/GenBank, EBI/EMBL, or DDBJ. Amino acid sequences of possible translation products for each ordered synthetic gene will also be screened. Purchasers of synthetic genes will also be screened in accordance with national guidelines. Furthermore, the IGSC companies have agreed to keep all screening, customer, and order records for at least eight years. IGSC companies have also reserved the right to refuse to...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Tania Fabo, Truthout | 02.28.2026
The reproductive tech company Orchid recently launched a genetic test that promises a whole genome sequencing report for embryos. It is the first such test commercially available to couples undergoing in vitro fertilization (IVF) and claims to detect things like...
By Pete Shanks
| 02.27.2026
Last month, we published “The Shameful Legacy of Tuskegee” which focused on a proposed experiment in Guinea-Bissau. The study’s plan echoed the notorious Tuskegee disaster, withholding safe, effective vaccines against hepatitis B from some newborns while inoculating others. It was to be financed by the U.S. but performed by a controversial Danish team. That project provoked a multi-national outcry, leading to a remarkable response from the World Health Organization:
WHO has significant concerns regarding the study’s scientific...
By Jenn White, NPR | 02.26.2026